FibroGen (NASDAQ: FGEN) reported Q4 EPS of $0.23, $0.30 better than the analyst estimate of ($0.07). Revenue for the quarter came in at $108.1 million versus the consensus estimate of $72.1 million.

For earnings history and earnings-related data on FibroGen (FGEN) click here.